Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Trillium Therapeutics Inc. (TRIL)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Dec-31-19Dec-31-17Dec-31-16Dec-31-15
   10-K10-KSourceSource20-F
Revenues  0.10.137.129.818.1
            Revenue growth  19.4% 24.7%65.0% 
Cost of goods sold  0.00.00.00.00.0
Gross profit  0.10.137.129.818.1
            Gross margin  100.0%100.0%100.0%100.0%100.0%
Selling, general and administrative   [+]36.35.741.033.73.2
Research and development  25.326.7   
Other operating expenses      18.1
EBITDA   [+]-60.9-31.74.74.0-2.4
            EBITDA margin  -41124.3%-25547.6%12.7%13.6%-13.2%
Depreciation  0.60.64.74.30.5
EBITA  -61.5-32.30.0-0.2-2.8
            EBITA margin  -41523.6%-26038.7%0.0%-0.8%-15.8%
Amortization of intangibles    3.93.70.3
EBIT   [+]-61.5-32.3-3.9-3.9-3.2
            EBIT margin  -41523.6%-26038.7%-10.4%-13.2%-17.6%
Interest income  2.00.6   
Other income (expense), net   [+]0.2-6.448.939.317.9
Pre-tax income  -59.2-38.145.135.414.7
Income taxes  0.10.00.0-3.70.0
            Tax rate    0.0% 0.0%
Net income  -59.3-38.10.00.00.0
            Net margin  -40098.6%-30711.3%0.0%0.0%0.0%
   
Basic EPS   [+]($0.70)($1.51)   
Diluted EPS   [+]($0.70)($1.51)   
   
Shares outstanding (basic)   [+]84.625.3   
Shares outstanding (diluted)   [+]84.625.3   
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy